US5460964A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for culturing hematopoietic cells
Assignee: MCGLAVE PHILIP B
•
Filing: 1993-03-17
•
Granted: 1995-10-24
•
Expires: 2013-03-17
Abstract
Abstract A method for culturing mammalian hematopoietic, preferably stem cells, is provided comprising maintaining a population of human hematopoietic cells in a non-contacting relationship to a population of cultured stromal cells, which populations are in preferably liquid stromal growth medium connection, so that the ability of the stem cells in said population to differentiate and self-replicate is maintained during an extended culture period.
Inventors
- 👤 Philip B. McGlave
- 👤 Catherine M. Verfaillie
- 👤 Jeffrey S. Miller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 14:38
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0647; C12N2501/00; C12N2501/20; C12N2501/21; C12N2501/23; C12N2501/30; C12N2501/38; C12N2501/39; C12N2502/00; C12N2502/13; C12N2502/1394
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
88 words
A cell culture method comprising culturing in vitro a population of human hematopoietic cells comprising stem cells or committed progenitor cells supported in a non-contacting relationship to a supported population of cultured stromal cells, which said populations are in a body of liquid stromal cell culture medium comprising an effective stimulatory amount of IL-3 and macrophage inflammatory protein-1α (MIP-1α) added thereto, so that the ability of the stem cells to self-replicate and differentiate is maintained or the ability of the committed progenitors to expand and differentiate is maintained.
Claim 2
Dependent Claim
88 words
A cell culture method comprising culturing in vitro a population of human hematopoietic cells comprising stem cells or committed progenitor cells supported in a non-contacting relationship to a supported population of cultured stromal cells, which said populations are in a body of liquid stromal cell culture medium comprising an effective stimulatory amount of IL-3 and macrophage inflammatory protein-1α (MIP-1α) added thereto, so that the ability of the stem cells to self-replicate and differentiate is maintained or the ability of the committed progenitors to expand and differentiate is maintained.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the hematopoietic cells consist essentially of committed progenitor cells.
Claim 4
Dependent Claim
12 words
The method of claim 1 wherein the hematopoietic cells comprise stem cells.
Claim 5
Dependent Claim
15 words
The method of claim 1 wherein the hematopoietic cells are derived from bone marrow cells.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein the hematopoietic cells are derived from peripheral blood or from newborn cord blood.
Claim 7
Dependent Claim
13 words
The method of claim 1 wherein the stem cells are CD34 + .
Claim 8
Dependent Claim
17 words
The method of claim 6 wherein the stem cells are Lin - CD34 + DR - .
Claim 9
Dependent Claim
17 words
The method of claim 1 wherein the stromal cells are human stromal cells or murine stromal cells.
Claim 10
Dependent Claim
24 words
The method of claim 1 wherein the hematopoietic cell population and the stromal cell population are cultured on discrete and separable cell culture substrata.
Claim 11
Dependent Claim
16 words
The method of claim 1 wherein the hematopoietic cell population is supported on a microporous membrane.
Claim 12
Dependent Claim
29 words
The method of claim 10 wherein the hematopoietic cell population is supported on a microporous membrane, which said membrane separates the stromal cell population from the hematopoietic cell population.
Claim 13
Dependent Claim
21 words
The method of claim 11 wherein the stromal cell population is adhered to the bottom of a plastic cell culture well.
Claim 14
Dependent Claim
21 words
The method of claim 1 wherein the hematopoietic cell population and the stromal cell population are separated by about 0.25-2 mm.
Claim 15
Independent Claim
24 words
The method of claims 1 or 9 wherein the liquid stromal cell growth medium is 25-100% exchanged at intervals of about 8 hrs-14 days.
Claim 16
Dependent Claim
31 words
The method of claim 9 wherein the liquid stromal cell growth medium is continuously circulated through a first chamber comprising said stromal cells and a second chamber comprising said hematopoietic cells.
Claim 17
Dependent Claim
24 words
The method of claim 15 wherein the hematopoietic cell population and the stromal cell population are adhered to the outside of discrete hollow fibers.
Claim 18
Dependent Claim
10 words
The method of claim 1 wherein the populations are allogeneic.
Claim 19
Dependent Claim
10 words
The method of claim 1 wherein the populations are autologous.
References Cited (Backward Citations)
US4342828A
Cited
US4873191A
Cited
US4714680A
Cited
US5035994B1
Cited
US4714680B1
Cited
US5035994A
Cited
US4965204A
Cited
WO1987006120A1
Cited
US4721096A
Cited
US4902783A
Cited
US4808611A
Cited
US5004681A
Cited
US5004681B1
Cited
US5192553A
Cited
EP0341966A2
Cited
US4946437A
Cited
EP0395355A1
Cited
US5061620A
Cited
EP0455482A2
Cited
US5104804A
Cited
US5139951A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-10-23 | 1999-04-24 | 1999-10-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-10-23 | 2003-04-24 | 2003-10-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-10-23 | 2007-04-24 | 2007-10-24 | $7700.00 | Window Closed / Lapsed |